Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/David Weinreich, Global Head of R&D and Chief Medical Officer
“People living with lupus continue to fa...